@
Valerian Thanks for the link and quote. Lemme just re-quote a part of it:
three doses of the COVID-19 NVX-CoV2373 vaccine significantly improved neutralization of the SARS-CoV-2 Omicron BA.4/BA.5 and BA.1 subvariants with responses that were comparable to those achieved with three mRNA vaccine doses.
They're saying 3 Novovax doses are comparable to 3 mRNA doses. Fair enough.
The next sentence says 2 Novovax doses have pretty good staying power, yet there is no staying power comparison to the mRNA vaccines.
THUS. Nothing in your quote says Novovax is in any way better than the mRNA vaccines.
AND. If you want an apples to apples comparison, the only one we have is against the original wildtype, where the mRNA vaccines showed 95% efficacy in trials of 30,000 subjects (Moderna) and 45.000 subject (Pfizer). These results are comperable to Novovax.
unless the FDA tries to surpress the Vaccine further.
Novovax uses cells from moths to grow spike proteins. Novovax got a LOT of gov't support, but was delayed due to manufacturing/purity problems:
The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.
Frankly, it's not at all surprising that Novovax and the mRNA vaccines are comparable, because they both result in spike proteins in your blood; they just have different mechanisms for getting those spike proteins there.